Cyclacel plummets on futility analysis

Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) dropped $2.15 (76%) to $0.68 after oral sapacitabine ( CYC682) failed a futility analysis of

Read the full 192 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE